In January 2021, we announced the NMPA had granted envafolimab NDA priority review. 8226; Higher anti-tumor efficacy. Tumor assessments were performed based on RECIST version 1.1. Starting from the 0.3 mg/kg cohort, a traditional "3+3" design was followed. All of the 18 enrolled subjects experienced TEAEs. Efficacy of dose escalation phase. As of the same date, three subjects had remained in the trial. The IND application filed by NCI cross references our IND application. These data were published in Investigational New Drugs in 2012. PD-1 and PD-L1 inhibitors collectively sold over $21 billion Worldwide in 2019. If TRC102 is approved, it could compete with other inhibitors of DNA repair. We currently do not have any sales or marketing capabilities or experience as a company. We hold an issued patent on further combinations of TRC102 in Europe. Recently, this period was extended to 8 years for all new drug approvals. Failure can occur at any stage of clinical development. The most common AE identified in the Phase 1/2 trial of TRC253 was QTcF prolongation. In July 2020, the FDA restarted domestic on-site inspections on a risk-based basis. Another drug may receive marketing approval prior to TRC 102. Accordingly, the market price of our common stock may decline. We may not be able to protect our intellectual property rights throughout the world. We cannot predict the initiatives that may be adopted in the future.
